Skip to main content
Log in

Bivalirudin and fondaparinux cost effective for NSTE-ACS

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

REFERENCE

  1. Maxwell CB, Holdford DA, Crouch MA, Patel DA.Cost-effectiveness analysis of anticoagulation strategies in non-ST-elevation acute coronary syndromes. Annals of Pharmacotherapy 43: 586-595, No. 4, Apr 2009

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bivalirudin and fondaparinux cost effective for NSTE-ACS. Pharmacoecon. Outcomes News 578, 4 (2009). https://doi.org/10.2165/00151234-200905780-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151234-200905780-00007

Keywords

Navigation